|ZFIN ID: ZDB-PUB-110719-26|
|Source:||Circulation research 109(6): 658-69 (Journal)|
|Registered Authors:||Ding, Yonghe, Ekker, Stephen C., Hoage, Tiffany R., Huang, Wei, Lin, Xueying, Sivasubbu, Sridhar, Sun, Xiaojing, Xu, Xiaolei|
|Keywords:||doxorubicin, cardiotoxicity, cardiomyopathy, target of rapamycin, zebrafish, anemia|
|PubMed:||21757652 Full text @ Circ. Res.|
Rationale: Although a cardioprotective function of target of rapamycin (TOR) signaling inhibition has been suggested by pharmacological studies using rapamycin, genetic evidences are still lacking. We explored adult zebrafish as a novel vertebrate model for dissecting signaling pathways in cardiomyopathy.
Objective: We generated the second adult zebrafish cardiomyopathy model induced by doxorubicin. By genetically analyzing both the doxorubicin and our previous established anemia-induced cardiomyopathy models, we decipher the functions of TOR signaling in cardiomyopathies of different etiology.
Methods and Results: Along the progression of both cardiomyopathy models, we detected dynamic TOR activity at different stages of pathogenesis as well as distinct effects of TOR signaling inhibition. Nevertheless, cardiac enlargement in both models can be effectively attenuated by inhibition of TOR signaling through short-term rapamycin treatment. To assess the long-term effects of TOR reduction, we used a zebrafish target of rapamycin (ztor) mutant identified from an insertional mutagenesis screen. We show that TOR haploinsufficiency in the ztor heterozygous fish improved cardiac function, prevented pathological remodeling events, and ultimately reduced mortality in both adult fish models of cardiomyopathy. Mechanistically, these cardioprotective effects are conveyed by the antihypertrophy, antiapoptosis, and proautophagy function of TOR signaling inhibition.